A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding everolimus to letrozole as preoperative therapy of primary breast cancer in postmenopausal women

Trial Profile

A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding everolimus to letrozole as preoperative therapy of primary breast cancer in postmenopausal women

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2015

At a glance

  • Drugs Everolimus (Primary) ; Letrozole
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2009 Primary endpoint results published in Journal of Clinical Oncology 27
    • 03 Jun 2008 Results reported at ASCO 2008.
    • 18 Dec 2007 Status changed from recruiting to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top